Web Desc
Antibodies as Drugs
Organizer(s): Nils Lonberg, Stephen M. Ansell and Edith Perez
Date: February 06 - 11, 2011
Location: Keystone Resort, Keystone, CO, USA
Sponsored by Bristol-Myers Squibb Company, Novo Nordisk A/S and Takeda Pharmaceutical Company Limited
Summary of Meeting:
The therapeutic antibody field has matured to the point where antibody based therapies have become commonly prescribed for many diseases, particularly in cancer and rheumatology. This conference will bring together basic scientists, translational clinicians, and pharmaceutical industry scientists engaged in antibody drug discovery and development. Interactive discussions of current state of the art and areas for future work in this field will provide the structure for this meeting.
Scholarship Deadline: October 6 2010
Discounted Abstract Deadline: October 6 2010
Abstract Deadline: November 8 2010
Discounted Registration Deadline: December 6 2010
We gratefully acknowledge additional support for this conference from:
Boehringer Ingelheim Pharmaceuticals, Inc.Bristol-Myers Squibb CompanyCephalonCovX Research LLC (Pfizer)Novo Nordisk A/STakeda Pharmaceutical Company Limited
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Abbott Laboratories

Alder Biopharmaceuticals, Inc.

Bristol-Myers Squibb Company

Genentech, Inc.

Genmab B.V.

ImmunoGen, Inc.

MedImmune

Micromet, Inc.

Seattle Genetics, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, February 06 | 3:00PM - 7:30PM
Registration
Room: Longs Peak Foyer


Sunday, February 06 | 5:00PM - 5:00PM
SuperBowl shown on the big screen with cash bar service avai
lable.
Room: Longs/Grays Peak


Sunday, February 06 | 6:15PM - 7:15PM
Refreshments
Room: Longs Peak Foyer


Sunday, February 06 | 7:15PM - 8:30PM
Welcome and Keynote Address
Room: Longs/Grays Peak

Speaker 1 of 1
Mark X. Sliwkowski, Genentech, Inc., USA
Multiple Approaches to Targeting ErbB/HER Receptors in Solid Tumors

Monday, February 07 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 1 of 8
* Paul W. H. I. Parren, Leiden University Medical Center, Netherlands

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 2 of 8
Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Bispecific Antibodies Designed for Polyclonal T Cell Engagement

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 3 of 8
Ian M. Tomlinson, GlaxoSmithKline, UK
Domain Antibodies for Human Therapy

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 4 of 8
Jeffrey V. Ravetch, Rockefeller University, USA
Hypersialylated Antibodies and Antibody Fragments for Immunomodulation

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 5 of 8
George J. Weiner, University of Iowa, USA
CDC and ADCC: Synergistic or Antagonistic Mechanisms?

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 6 of 8
Adrian Wiestner, NHLBI, National Institutes of Health, USA
Short Talk: Targeting the Fcmu-receptor: mAbs and Fc-Derived Protein Scaffolds Offer Complementary Approaches for Cancer Therapy

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 7 of 8
Philip D. Bardwell, AbbVie Bioresearch Center, USA
Short Talk: Re-Targeting Effector T Cells to Tumor Cell Targets using Dual Variable Domain-Immunoglobulins (DVD-IgTM)

Monday, February 07 | 8:00AM - 11:30AM
New Antibody Platform Technologies I: Fc Modifications, Bisp
ecifics, and Fragments

Room: Longs/Grays Peak

Speaker 8 of 8
Margaret E. Ackerman, Dartmouth College, USA
Short Talk: Tuning the Antibody Response: Natural Modulation of Antibody Glycosylation and Effector Function in HIV Infection

Monday, February 07 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Monday, February 07 | 11:30AM - 1:00PM
Poster Setup
Room: Quandary Peak


Monday, February 07 | 11:30AM - 11:30AM
On Own for Lunch and Recreation


Monday, February 07 | 1:00PM - 10:00PM
Poster Viewing
Room: Quandary Peak


Monday, February 07 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Monday, February 07 | 5:00PM - 7:00PM
New Antibody Platform Technologies II: Payloads
Room: Longs/Grays Peak

Speaker 1 of 5
* Mark X. Sliwkowski, Genentech, Inc., USA

Monday, February 07 | 5:00PM - 7:00PM
New Antibody Platform Technologies II: Payloads
Room: Longs/Grays Peak

Speaker 2 of 5
Nils Lonberg, Canaan Partners, USA
Alkylating Agent Drug Conjugates

Monday, February 07 | 5:00PM - 7:00PM
New Antibody Platform Technologies II: Payloads
Room: Longs/Grays Peak

Speaker 3 of 5
John M. Lambert, USA
Maytansinoids as Payloads for ADCs: Effective Drug Products for Treating Cancer

Monday, February 07 | 5:00PM - 7:00PM
New Antibody Platform Technologies II: Payloads
Room: Longs/Grays Peak

Speaker 4 of 5
Peter D. Senter, Seattle Genetics Inc., USA
Empowered Antibodies for Cancer Therapy

Monday, February 07 | 5:00PM - 7:00PM
New Antibody Platform Technologies II: Payloads
Room: Longs/Grays Peak

Speaker 5 of 5
Christoph Rader, The Scripps Research Institute, USA
Short Talk: A Sequential Program and Arm Strategy for Fc Fragments with a C-Terminal Selenocysteine

Monday, February 07 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Quandary Peak


Monday, February 07 | 7:30PM - 10:00PM
Poster Session 1
Room: Quandary Peak


Tuesday, February 08 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Tuesday, February 08 | 8:00AM - 11:15AM
Immune Modulation I: Infectious Disease and Cancer
Room: Longs/Grays Peak

Speaker 1 of 6
* Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia

Tuesday, February 08 | 8:00AM - 11:15AM
Immune Modulation I: Infectious Disease and Cancer
Room: Longs/Grays Peak

Speaker 2 of 6
Ian A. Wilson, The Scripps Research Institute, USA
Antibody Recognition of HIV-1 and Influenza

Tuesday, February 08 | 8:00AM - 11:15AM
Immune Modulation I: Infectious Disease and Cancer
Room: Longs/Grays Peak

Speaker 3 of 6
Don M. Benson, Ohio State University Comprehensive Cancer Center, USA
A Role for PD-1 in NK Cell Immunity Against Multiple Myeloma

Tuesday, February 08 | 8:00AM - 11:15AM
Immune Modulation I: Infectious Disease and Cancer
Room: Longs/Grays Peak

Speaker 4 of 6
James E. Crowe, Jr., Vanderbilt University Medical Center, USA
Naturally Occurring Human Antibody Responses to Viral Infections

Tuesday, February 08 | 8:00AM - 11:15AM
Immune Modulation I: Infectious Disease and Cancer
Room: Longs/Grays Peak

Speaker 5 of 6
Alan J. Korman, Vir Biotechnology, Inc., USA
Lag-3 Targeted Immunotherapy

Tuesday, February 08 | 8:00AM - 11:15AM
Immune Modulation I: Infectious Disease and Cancer
Room: Longs/Grays Peak

Speaker 6 of 6
Gary J. Nabel, Sanofi, USA
Identification of Broadly Neutralizing Human MAbs to HIV-1: Applications to Vaccine Design, Passive Protection and HIV Therapy

Tuesday, February 08 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Tuesday, February 08 | 11:15AM - 1:00PM
Poster Setup
Room: Quandary Peak


Tuesday, February 08 | 11:15AM - 11:15AM
On Own for Lunch and Recreation


Tuesday, February 08 | 1:00PM - 10:00PM
Poster Viewing
Room: Quandary Peak


Tuesday, February 08 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Tuesday, February 08 | 5:00PM - 7:00PM
Immune Modulation II: Cancer
Room: Longs/Grays Peak

Speaker 1 of 5
* Alan J. Korman, Vir Biotechnology, Inc., USA

Tuesday, February 08 | 5:00PM - 7:00PM
Immune Modulation II: Cancer
Room: Longs/Grays Peak

Speaker 2 of 5
Kevin Heller, Bristol-Myers Squibb Company, USA
CTLA-4 Blockade for Cancer Immunotherapy

Tuesday, February 08 | 5:00PM - 7:00PM
Immune Modulation II: Cancer
Room: Longs/Grays Peak

Speaker 3 of 5
Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
B7-H1/PD-1 Blockade for Cancer Immunotherapy

Tuesday, February 08 | 5:00PM - 7:00PM
Immune Modulation II: Cancer
Room: Longs/Grays Peak

Speaker 4 of 5
Paul M. Sondel, University of Wisconsin-Madison, USA
Cell-Mediated Destruction of Neuroblastoma and Melanoma Facilitated by Anti-GD2 Reagents ch14.18 and hu14.18-IL2

Tuesday, February 08 | 5:00PM - 7:00PM
Immune Modulation II: Cancer
Room: Longs/Grays Peak

Speaker 5 of 5
Andrew D. Weinberg, Earle A. Chiles Research Institute/Oregon Health & Science University, USA
Short Talk: Reshaping CD4 and CD8 Memory T Cell Proliferation by Treating Cancer Patients with an Anti-OX40 Ab: Immunologic and Clinical Assessment of a Phase I Trial

Tuesday, February 08 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Quandary Peak


Tuesday, February 08 | 7:30PM - 10:00PM
Poster Session 2
Room: Quandary Peak


Wednesday, February 09 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 1 of 8
* Stephen M. Ansell, Mayo Clinic, USA

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 2 of 8
Trudi M. Veldman, AbbVie, Inc., USA
Modulation of the IL-1 Axis for RA and OA using DVD-IgTM Technology

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 3 of 8
Barbara White, Corbus Pharmaceuticals, USA
Blocking Type I Interferons in Systemic Lupus Erythematosus and Other Autoimmune Diseases

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 4 of 8
Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Combination Chemo-Immunotherapy

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 5 of 8
Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Checkpoint Blockade Combination Therapies

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 6 of 8
Eric Dobrzynski, GlaxoSmithKline, USA
Short Talk: PanELR: A High Affinity Neutralizing Monoclonal Antibody Targeting Multiple Human Pro-Inflammatory ELRCXC Chemokines

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 7 of 8
Stephen A. Beers, University of Southampton, UK
Short Talk: Re-Programming Macrophages to Enhance Antibody Immunotherapy

Wednesday, February 09 | 8:00AM - 11:30AM
Immune Modulation III: Inflammatory Disease and Cancer
Room: Longs/Grays Peak

Speaker 8 of 8
Joe Ponte, Tolerx, Inc., USA
Short Talk: In vitro and in vivo Characterization of TRX518, a Novel Anti-huGITR Monoclonal Antibody and New Phase 1 Clinical Trial Candidate

Wednesday, February 09 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Wednesday, February 09 | 11:30AM - 11:30AM
On Own for Lunch and Recreation


Wednesday, February 09 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Wednesday, February 09 | 5:00PM - 7:00PM
Cancer I
Room: Longs/Grays Peak

Speaker 1 of 5
* Ronald P. Taylor, University of Virginia School of Medicine, USA

Wednesday, February 09 | 5:00PM - 7:00PM
Cancer I
Room: Longs/Grays Peak

Speaker 2 of 5
Stephen M. Ansell, Mayo Clinic, USA
Therapeutic Antibody Combinations in the Treatment of Lymphoproliferative Disorders

Wednesday, February 09 | 5:00PM - 7:00PM
Cancer I
Room: Longs/Grays Peak

Speaker 3 of 5
Ronald Levy, Stanford University, USA
Combination Therapy to Enhance Antibody ADCC Activity: CD137 MAbs as an Activator of NK Cell Function

Wednesday, February 09 | 5:00PM - 7:00PM
Cancer I
Room: Longs/Grays Peak

Speaker 4 of 5
Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
CD38 as a Target for MM

Wednesday, February 09 | 5:00PM - 7:00PM
Cancer I
Room: Longs/Grays Peak

Speaker 5 of 5
Waleed Alduaij, University of Manchester, Paterson Institute of Cancer Research, UK
Short Talk: Novel Type II Anti-CD20 Monoclonal Antibody (GA101) Evokes Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Malignancies

Wednesday, February 09 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Quandary Peak


Thursday, February 10 | 7:00AM - 8:00AM
Breakfast
Room: Quandary Peak


Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 1 of 7
* Nils Lonberg, Canaan Partners, USA

Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 2 of 7
Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
Effective Functions of CD20 Antibodies

Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 3 of 7
Georgiana K. Ellis, Seattle Cancer Care Alliance, USA
Cancer, Bone Health and Denosumab

Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 4 of 7
Eric L. Sievers, Seattle Genetics, Inc., USA
Empowered Antibodies for Cancer Therapy: The Case of Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 5 of 7
Wayne Chu, Genentech, Inc., USA
Trastuzumab-DM1 (T-DM1) Antibody-Drug Conjugate (ADC): Optimizing HER2-Targeted Cancer Therapy

Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 6 of 7
Aaron K. Sato, Twist Bioscience, USA
Short Talk: Wnt Pathway Inhibition Decreases Tumorigenicity and Promotes Differentiation of Human Tumors

Thursday, February 10 | 8:00AM - 11:15AM
Cancer II
Room: Longs/Grays Peak

Speaker 7 of 7
Helle Jane Jacobsen, Symphogen A/S, Denmark
Short Talk: Sym004: A Novel Synergistic Anti–Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

Thursday, February 10 | 9:20AM - 9:40AM
Coffee Break
Room: Longs Peak Foyer


Thursday, February 10 | 11:15AM - 11:15AM
On Own for Lunch and Recreation


Thursday, February 10 | 4:30PM - 5:00PM
Coffee Available
Room: Longs Peak Foyer


Thursday, February 10 | 5:00PM - 7:00PM
Cancer III
Room: Longs/Grays Peak

Speaker 1 of 5
* Ronald Levy, Stanford University, USA

Thursday, February 10 | 5:00PM - 7:00PM
Cancer III
Room: Longs/Grays Peak

Speaker 2 of 5
Ronald P. Taylor, University of Virginia School of Medicine, USA
Antigen Shaving as a Mechanism of Resistance to Antibody Therapy

Thursday, February 10 | 5:00PM - 7:00PM
Cancer III
Room: Longs/Grays Peak

Speaker 3 of 5
Roy S. Herbst, University of Texas MD Anderson Cancer Center, USA
Antibodies Targeting Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor in Advanced Non-Small Cell Lung Cancer

Thursday, February 10 | 5:00PM - 7:00PM
Cancer III
Room: Longs/Grays Peak

Speaker 4 of 5
John A. Latham, Alder BioPharmaceuticals, USA
Therapeutic Intervention in IL-6-Driven Disease: Clinical Experience with ALD518

Thursday, February 10 | 5:00PM - 7:00PM
Cancer III
Room: Longs/Grays Peak

Speaker 5 of 5
Mark S. Cragg, University of Southampton, UK
Short Talk: Controlling Antigenic Modulation - Key Role of FcgammaRIIb in Regulating the Response to Rituximab

Thursday, February 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Quandary Peak


Thursday, February 10 | 8:00PM - 11:00PM
Entertainment
Room: Quandary Peak


Thursday, February 10 | 8:00PM - 11:00PM
Cash Bar
Room: Quandary Peak


Friday, February 11 | 10:25AM - 10:25AM
Departure


*Session Chair.